pyrazines has been researched along with iloprost in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Clozel, M; Ernst, R; Hess, P; Morrison, K; Studer, R | 1 |
| Benyahia, C; Boukais, K; Clapp, L; Danel, C; Fabre, A; Gomez, I; Leséche, G; Longrois, D; Norel, X; Silverstein, A | 1 |
| Clapp, LH; Ledwozyw, A; Orie, NN; Whittle, BJ; Williams, DJ | 1 |
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
| Benza, RL; Raina, A; Verlinden, NJ; Walter, C | 1 |
| Akashi, K; Arinobu, Y; Ayano, M; Fukata, M; Higashioka, K; Horiuchi, T; Imabayashi, K; Kashiwado, Y; Kawano, S; Kimoto, Y; Mitoma, H; Niiro, H; Ono, N; Saiki, C; Yokoyama, T | 1 |
6 other study(ies) available for pyrazines and iloprost
| Article | Year |
|---|---|
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function.
Topics: Acetamides; Animals; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Gastric Emptying; Gastrointestinal Transit; Humans; Iloprost; Male; Muscle Contraction; Pulmonary Artery; Pyrazines; Rats; Receptors, Epoprostenol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach | 2010 |
A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Topics: Acetates; Aged; Drug Evaluation, Preclinical; Epoprostenol; Female; Humans; Iloprost; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Molecular Mimicry; Pulmonary Artery; Pulmonary Veins; Pyrazines; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP4 Subtype; Vasodilation; Vasodilator Agents | 2013 |
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Topics: Acetamides; Acetates; Animals; Benzofurans; Benzyl Compounds; Epoprostenol; Female; Iloprost; Imidazoles; Male; Propionates; Pulmonary Artery; Pulmonary Veins; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2013 |
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |
A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
Topics: Acetamides; Antihypertensive Agents; Female; Humans; Hypertension, Pulmonary; Iloprost; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines | 2021 |
Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Topics: Acetamides; Adult; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Iloprost; Lupus Erythematosus, Systemic; Pulmonary Arterial Hypertension; Pyrazines; Quality of Life | 2022 |